Improvement in Renal Function and Bone Mineral Density after a Switch from Tenofovir/Emtricitabine plus Ritonavir-Boosted Protease Inhibitor to Raltegravir plus Nevirapine: A Pilot Study
Free accessResearch articleFirst published online April, 2016
Improvement in Renal Function and Bone Mineral Density after a Switch from Tenofovir/Emtricitabine plus Ritonavir-Boosted Protease Inhibitor to Raltegravir plus Nevirapine: A Pilot Study
The antiretroviral regimens including tenofovir and a ritonavir-boosted protease inhibitor (r/PI) have been associated with a reduced bone mineral density (BMD), increased bone turnover markers and renal tubular dysfunction.
Methods
An observational, prospective study was performed including HIV-1-infected, virologically suppressed patients treated with tenofovir/emtricitabine plus an r/PI for at least 12 months who switched to raltegravir plus nevirapine. The primary end point was changes after 48 weeks in estimated glomerular filtration rate (eGFR), prevalence of tubular dysfunction, BMD and concentration of two serum markers of bone turnover: collagen type-1 cross-linked C-telopeptide (CTX) and bone-specific alkaline phosphatase (BAP).
Results
A total of 46 patients were enrolled: 78% were male, 96% were Caucasian, the mean age was 45 years and the mean CD4+ T-lymphocyte count was 681 cells/mm3. A renal impairment was present in 72% of patients and was the main reason for the switch. After 48 weeks, prevalence of proximal tubular dysfunction decreased significantly (-72%; P<0.001), whereas the mean value of eGFR did not change significantly. At the same time, after 48 weeks a significant increase in both lumbar spine and total hip BMD, T-score and Z-score was reported (+11.5% in lumbar spine T-score; P<0.001), and there was a significant reduction in both CTX and BAP mean serum concentrations (-15% and -13%, respectively; P<0.001). Two (4.3%) patients had virological failure due to suboptimal adherence and one (2.2%) subject discontinued treatment due to a skin rash.
Conclusions
Switching virologically suppressed patients from tenofovir/emtricitabine plus one r/PI to raltegravir plus nevirapine after 48 weeks significantly improved proximal tubular function, increased BMD and reduced serum markers of bone turnover.
References
1.
PalellaF.J., DelaneyK.M., MoormanA.C.Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.N Engl J Med1998; 338: 853–860.
2.
PalellaF.J., BakerR.K., MoormanA.C.Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.J Acquir Immune Defic Syndr2006; 43: 27–34.
3.
RölingJ., SchmidH., FischerederM.HIV-associated renal diseases and highly active antiretroviral therapy-induced nephropathy.Clin Infect Dis2006; 42: 1488–1495.
4.
MaggiP., BartolozziD., BonfantiP.Renal complications in HIV disease: between present and future.AIDS Rev2012; 14: 37–53.
5.
OvertonE.T., NurutdinovaD., FreemanJ., SeyfriedW., MondyK.Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy.HIV Med2009; 10: 343–350.
6.
Crum-CianfloneN., GanesanA., Teneza-MoraN.Prevalence and factors associated with renal dysfunction among HIV-infected patients.AIDS Patient Care STDS2010; 24: 353–360.
7.
MocroftA., KirkO., ReissP.Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients.AIDS2010; 24: 1667–1678.
CalzaL., TrapaniF., SalvadoriC.Incidence of renal toxicity in HIV-infected, antiretroviral-naive patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir or lopinavir/ritonavir.Scand J Infect Dis2013; 45: 147–154.
10.
BrownT.T., QaqishR.B.Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.AIDS2006; 20: 2165–2174.
11.
StellbrinkH.J., OrkinC., ArribasJ.R.Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.Clin Infect Dis2010; 51: 963–972.
12.
GallantJ.E., StaszewkiS., PozniakA.L.Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.JAMA2004; 292: 191–201.
13.
McComseyG.A., KitchD., DaarE.S.Bone mineral density and fractures in antiretroviral-naïve persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir.ritonavir: AIDS Clinical Trial Group A5224s, a substudy of ACTG A5202.J Infect Dis2011; 203: 1791–1801.
14.
BedimoR., MaaloufN.M., ZhangS., DrechslerH., TebasP.Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents.AIDS2012; 26: 825–831.
15.
CalzaL.Renal toxicity associated with antiretroviral therapy.HIV Clin Trials2012; 13: 189–211.
16.
BrownT.T., HoyJ., BorderiM.Recommendations for evaluation and management of bone disease in HIV.Clin Infect Dis2015; 60: 1242–1251.
17.
UsachI., MelisV., PerisJ.E.Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability.J Int AIDS Soc2013; 16: 1–14.
18.
CurranA., MartinezE., SaumoyM.Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy.AIDS2012; 26: 475–481.
19.
LeveyA.S., StevensL.A., SchmidC.H.CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A New Equation to Estimate Glomerular Filtration Rate.Ann Intern Med2009; 150: 604–612.
20.
University of Sheffield: World Health Organization Collaborating Centre for Metabolic Bone Disease.FRAX® WHO Fracture Risk Assessment Tool (using Italian-specific dataset). (Accessed 29 July 2015.) Available from https://www.shef.ac.uk/FRAX/tool.aspx?country.
21.
NishijimaT., GatanagaH., ShimboT.Switching tenofovir/emtricitabine plus lopinavir/r to raltegravir plus darunavir/r in patients with suppressed viral load did not result in improvement of renal function but could sustain viral suppression: a randomized multicenter trial.PLoS ONE2013; 8: e73639.
22.
NegredoE., Diez-PérezA., BonjochA.Switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: changes in bone turnover markers and circulating sclerostin levels.J Antimicrob Chemother2015; 70: 2104–2107.
23.
NegredoE., DomingoP., Perez-AlvarezN.Improvement in bone mineral density after switching from tenofovir to abacavir in HIV-1-infected patients with low bone mineral density: two-centre randomized pilot study (OsteoTDF study).J Antimicrob Chemother2014; 69: 3368–3371.
24.
MartinA., MooreC., MallonP.W.Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ ritonavir compared with standard second line therapy.AIDS2013; 27: 2403–2411.
25.
WohlD.A., BhattiL., SmallC.B.The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.HIV Med2015; doi: 10.1111/hiv.12281.
26.
BlochM., TongW.W.Y., HoyJ.Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks.HIV Med2014; 15: 373–380.
27.
ReliquetV., ChirouzeC., AllavenaC.Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.Antivir Ther2014; 19: 117–123.
28.
LucasG.M., RossM.J., StockP.G.Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America.Clin Infect Dis2014; 59: e96–e138.
29.
MartinA., BlochM., AminJ.Simplification of antiretroviral therapy with tenofovir/emtricitabine or abacavir/lamivudine: a randomized, 96-week trial.Clin Infect Dis2009; 49: 1591–1601.
30.
DeJesusE., YoungB., Morales-RamirezJ.O.Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.J Acquir Immune Defic Syndr2009; 51: 163–174.
31.
MartínezE., LarrousseM., LibreJ.M.Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study.AIDS2010; 24: 1697–1707.
